Ribosome Inhibitors
1 drugsAbout Ribosome
The ribosome is a complex molecular machine in all living cells responsible for protein synthesis, translating genetic code into functional proteins essential for cellular processes.
The ribosome's fundamental role in protein production makes it a compelling therapeutic target, though currently there is no genetic evidence directly linking it to specific diseases.
There is one FDA-approved drug, ARIKAYCE KIT, targeting the ribosome; it is a small molecule with 9 indications and falls under the 'Other' therapeutic area.
Top Ribosome Drugs
INSMED INC is the only company with an approved drug targeting the ribosome.
Low competition suggests high barriers to entry or untapped potential in targeting the ribosome.
Ribosome Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Ribosome, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel approaches like biologics.
Ribosome Clinical Trials 27 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Ribosome. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 1 | 100% |
| Phase 2 | 10 | 3 | 3 | 4 | 50% |
| Phase 3 | 5 | 5 | 0 | 0 | 100% |
| Phase 4 | 9 | 6 | 1 | 2 | 86% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Ribosome Drug Approval Timeline (2018 - 2018)
The first and most recent drug approval was ARIKAYCE KIT in 2018.
The single approval indicates a potentially unsaturated market with room for new ribosome-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 21 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Ribosome. A trial counts if an approved drug acting on Ribosome is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.